Biofil Chemicals (BIOFILCHEM)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Completely debt-free balance sheet with Debt/Equity at 0.00, limiting financial risk.
• Promoter holding of 46.79% provides reasonable alignment with minority shareholders.
• ROE of 15.08% is positive despite the small earnings base.
• Price is closer to the 52-week low of ₹25.60 than the high of ₹46.34, offering a lower entry point for speculative recovery.
• Low absolute market cap of ₹52 Cr could attract special-situation or turnaround investors.

Concerns

• Sales growth of -93.94% indicates a collapse in business activity; latest quarterly sales are only ₹1 Cr.
• Profit growth is -50.00%, and latest quarter net profit is effectively ₹0 Cr.
• Piotroski F-Score of 3/9 suggests weak overall financial health.
• Valuation is not cheap at P/E of 18.82 and P/B of 3.05, especially with ROCE of just 4.12% and no dividend yield.

AI Analysis

When I look at Biofil Chemicals, I first ask what this business earns. It has a market cap of ₹52 Cr, yet latest quarterly sales are just ₹1 Cr. That annualizes to roughly ₹4 Cr, so I am effectively paying about 13 times sales for a company whose reported sales growth is down 93.94%. That is not a wonderful business. Graham taught me to look for margin of safety. A P/B of 3.05 gives me no comfort when book value is ₹10.95 and the price is ₹33.39. The balance sheet is debt-free, which is good, but zero debt is not a moat. ROCE is a weak 4.12% — I could likely earn more in fixed income. ROE of 15.08% looks respectable, but with profit growth down 50% and a Piotroski F-Score of only 3/9, that return may be fragile or distorted by a shrunken base. Promoter holding of 46.79% is decent, yet good ownership does not replace bad economics. The dividend yield is zero, so as a minority shareholder I am relying entirely on recovery. I cannot call this a fast grower or a stalwart. Collapsing sales and negligible latest-quarter profit tell me this is a turnaround situation at best. I would need evidence that sales have stabilized, that margins are sustainable, and that the company can actually deploy its equity profitably. Until then, the price offers no margin of safety. This looks like a cigar butt — maybe one puff, but not a compounder.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer